GILEAD SCIENCES, INC. Share-based Payment Arrangement, Expense, after Tax
GILEAD SCIENCES, INC. (GILD) reported Share-based Payment Arrangement, Expense, after Tax of $640.00 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-24.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax · last filed 2026-02-24
- GILEAD SCIENCES, INC. share-based payment arrangement, expense, after tax for the quarter ending 2015-12-31 was $67.00M, a 15.19% decline year-over-year.
- GILEAD SCIENCES, INC. share-based payment arrangement, expense, after tax for the quarter ending 2015-09-30 was $44.00M, a 46.34% decline year-over-year.
- GILEAD SCIENCES, INC. share-based payment arrangement, expense, after tax for the quarter ending 2015-06-30 was $71.00M, a 1.39% decline year-over-year.
- GILEAD SCIENCES, INC. share-based payment arrangement, expense, after tax for the quarter ending 2015-03-31 was $69.00M, a 9.52% increase year-over-year.
- GILEAD SCIENCES, INC. share-based payment arrangement, expense, after tax for fiscal 2025 was $640.00M, a 17.63% decline from fiscal 2024.
- GILEAD SCIENCES, INC. share-based payment arrangement, expense, after tax for fiscal 2024 was $777.00M, a 23.33% increase from fiscal 2023.
- GILEAD SCIENCES, INC. share-based payment arrangement, expense, after tax for fiscal 2023 was $630.00M, a 13.92% increase from fiscal 2022.
- GILEAD SCIENCES, INC. share-based payment arrangement, expense, after tax for fiscal 2022 was $553.00M, a 3.36% increase from fiscal 2021.
| Period end | Share-based Payment Arrangement, Expense, after Tax 3 month | Share-based Payment Arrangement, Expense, after Tax 3 month as first filed | Share-based Payment Arrangement, Expense, after Tax 6 month | Share-based Payment Arrangement, Expense, after Tax 6 month as first filed | Share-based Payment Arrangement, Expense, after Tax 9 month | Share-based Payment Arrangement, Expense, after Tax 9 month as first filed | Share-based Payment Arrangement, Expense, after Tax 12 month | Share-based Payment Arrangement, Expense, after Tax 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | $640.00M 10-K · filed 2026-02-24 | |||||||
| 2024-12-31 | $777.00M 10-K · filed 2026-02-24 | |||||||
| 2023-12-31 | $630.00M 10-K · filed 2026-02-24 | |||||||
| 2022-12-31 | $553.00M 10-K · filed 2025-02-28 | |||||||
| 2021-12-31 | $535.00M 10-K · filed 2024-02-23 | |||||||
| 2020-12-31 | $854.00M 10-K · filed 2023-02-22 | |||||||
| 2019-12-31 | $638.00M 10-K · filed 2022-02-23 | |||||||
| 2018-12-31 | $681.00M 10-K · filed 2021-02-25 | |||||||
| 2017-12-31 | $369.00M 10-K · filed 2020-02-25 | |||||||
| 2016-12-31 | $276.00M 10-K · filed 2019-02-26 | |||||||
| 2015-12-31 | $67.00M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-27 | $111.00M derived: sum of 2 quarters · filed 2018-02-27 | $182.00M derived: sum of 3 quarters · filed 2018-02-27 | $251.00M 10-K · filed 2018-02-27 | ||||
| 2015-09-30 | $44.00M 10-Q · filed 2015-11-04 | $115.00M derived: sum of 2 quarters · filed 2015-11-04 | $184.00M 10-Q · filed 2015-11-04 | $263.00M derived: sum of 4 quarters · filed 2017-02-27 | ||||
| 2015-06-30 | $71.00M 10-Q · filed 2015-08-05 | $140.00M 10-Q · filed 2015-08-05 | $219.00M derived: sum of 3 quarters · filed 2017-02-27 | $301.00M derived: sum of 4 quarters · filed 2017-02-27 | ||||
| 2015-03-31 | $69.00M 10-Q · filed 2015-05-08 | $148.00M derived: sum of 2 quarters · filed 2017-02-27 | $230.00M derived: sum of 3 quarters · filed 2017-02-27 | $302.00M derived: sum of 4 quarters · filed 2017-02-27 | ||||
| 2014-12-31 | $79.00M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-27 | $161.00M derived: sum of 2 quarters · filed 2017-02-27 | $233.00M derived: sum of 3 quarters · filed 2017-02-27 | $296.00M 10-K · filed 2017-02-27 | ||||
| 2014-09-30 | $82.00M 10-Q · filed 2015-11-04 | $81.26M 10-Q · filed 2014-11-05 | $154.00M derived: sum of 2 quarters · filed 2015-11-04 | $217.00M 10-Q · filed 2015-11-04 | $216.60M 10-Q · filed 2014-11-05 | $269.67M derived: sum of 4 quarters · filed 2016-02-24 | ||
| 2014-06-30 | $72.00M 10-Q · filed 2015-08-05 | $72.20M 10-Q · filed 2014-08-04 | $135.00M 10-Q · filed 2015-08-05 | $135.34M 10-Q · filed 2014-08-04 | $187.66M derived: sum of 3 quarters · filed 2016-02-24 | $234.24M derived: sum of 4 quarters · filed 2016-02-24 | ||
| 2014-03-31 | $63.00M 10-Q · filed 2015-05-08 | $63.14M 10-Q · filed 2014-05-07 | $115.67M derived: sum of 2 quarters · filed 2016-02-24 | $162.24M derived: sum of 3 quarters · filed 2016-02-24 | $202.62M derived: sum of 4 quarters · filed 2016-02-24 | |||
| 2013-12-31 | $52.66M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-24 | $99.24M derived: sum of 2 quarters · filed 2016-02-24 | $139.62M derived: sum of 3 quarters · filed 2016-02-24 | $185.00M 10-K · filed 2016-02-24 | $185.30M 10-K · filed 2014-02-25 | |||
| 2013-09-30 | $46.58M 10-Q · filed 2014-11-05 | $86.95M derived: sum of 2 quarters · filed 2014-11-05 | $132.34M 10-Q · filed 2014-11-05 | $175.05M derived: sum of 4 quarters · filed 2015-02-25 | ||||
| 2013-06-30 | $40.38M 10-Q · filed 2014-08-04 | $85.76M 10-Q · filed 2014-08-04 | $128.48M derived: sum of 3 quarters · filed 2015-02-25 | $167.92M derived: sum of 4 quarters · filed 2015-02-25 | ||||
| 2013-03-31 | $45.38M 10-Q · filed 2014-05-07 | $88.10M derived: sum of 2 quarters · filed 2015-02-25 | $127.54M derived: sum of 3 quarters · filed 2015-02-25 | $162.78M derived: sum of 4 quarters · filed 2015-02-25 | ||||
| 2012-12-31 | $42.72M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-25 | $82.16M derived: sum of 2 quarters · filed 2015-02-25 | $117.40M derived: sum of 3 quarters · filed 2015-02-25 | $347.00M 10-K · filed 2015-02-25 | $346.70M 10-K · filed 2013-02-27 | |||
| 2012-09-30 | $39.44M 10-Q · filed 2013-10-31 | $74.68M derived: sum of 2 quarters · filed 2013-10-31 | $304.28M 10-Q · filed 2013-10-31 | $339.58M derived: sum of 4 quarters · filed 2014-02-25 | ||||
| 2012-06-30 | $35.24M 10-Q · filed 2013-08-01 | $264.84M 10-Q · filed 2013-08-01 | $300.14M derived: sum of 3 quarters · filed 2014-02-25 | $335.36M derived: sum of 4 quarters · filed 2014-02-25 | ||||
| 2012-03-31 | $229.60M 10-Q · filed 2013-05-08 | $264.91M derived: sum of 2 quarters · filed 2014-02-25 | $300.13M derived: sum of 3 quarters · filed 2014-02-25 | $338.04M derived: sum of 4 quarters · filed 2014-02-25 | ||||
| 2011-12-31 | $35.30M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-25 | $70.52M derived: sum of 2 quarters · filed 2014-02-25 | $108.44M derived: sum of 3 quarters · filed 2014-02-25 | $145.05M 10-K · filed 2014-02-25 | ||||
| 2011-09-30 | $35.22M 10-Q · filed 2012-11-06 | $73.14M derived: sum of 2 quarters · filed 2012-11-06 | $109.75M 10-Q · filed 2012-11-06 | $150.84M derived: sum of 4 quarters · filed 2013-02-27 | ||||
| 2011-06-30 | $37.91M 10-Q · filed 2012-08-01 | $74.53M 10-Q · filed 2012-08-01 | $115.62M derived: sum of 3 quarters · filed 2013-02-27 | $153.43M derived: sum of 4 quarters · filed 2013-02-27 | ||||
| 2011-03-31 | $36.61M 10-Q · filed 2012-05-04 | $77.70M derived: sum of 2 quarters · filed 2013-02-27 | $115.52M derived: sum of 3 quarters · filed 2013-02-27 | $149.91M derived: sum of 4 quarters · filed 2013-02-27 | ||||
| 2010-12-31 | $41.09M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-27 | $78.90M derived: sum of 2 quarters · filed 2013-02-27 | $113.30M derived: sum of 3 quarters · filed 2013-02-27 | $147.71M 10-K · filed 2013-02-27 | ||||
| 2010-09-30 | $37.81M 10-Q · filed 2011-11-04 | $72.21M derived: sum of 2 quarters · filed 2011-11-04 | $106.62M 10-Q · filed 2011-11-04 | |||||
| 2010-06-30 | $34.40M 10-Q · filed 2011-08-05 | $68.81M 10-Q · filed 2011-08-05 | ||||||
| 2009-12-31 | $139.27M 10-K · filed 2012-02-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMGEN INC (AMGN) | United States | $219.567B | 22.39 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |